Clinical Trial Update: SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD) [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluating a SEMA4D blocker in Alzheimer's disease assessed safety and brain metabolic activity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Pepinemab (VX15/2503) (pepinemab)

Snippet

Sponsor: Vaccinex Inc. | Conditions: Alzheimer Disease | Phase 1, Phase 2 | Status: COMPLETED